IFP Advisors Inc Lowers Holdings in Pfizer Inc. (NYSE:PFE)

IFP Advisors Inc trimmed its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 13.3% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,339 shares of the biopharmaceutical company's stock after selling 30,766 shares during the period. IFP Advisors Inc's holdings in Pfizer were worth $5,102,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of PFE. OneAscent Financial Services LLC boosted its stake in shares of Pfizer by 112.1% in the 1st quarter. OneAscent Financial Services LLC now owns 78,480 shares of the biopharmaceutical company's stock valued at $1,948,000 after purchasing an additional 41,481 shares in the last quarter. Elyxium Wealth LLC boosted its stake in shares of Pfizer by 108.6% in the 1st quarter. Elyxium Wealth LLC now owns 25,246 shares of the biopharmaceutical company's stock valued at $640,000 after purchasing an additional 13,144 shares in the last quarter. Berkeley Capital Partners LLC boosted its stake in shares of Pfizer by 4.1% in the 1st quarter. Berkeley Capital Partners LLC now owns 72,044 shares of the biopharmaceutical company's stock valued at $1,826,000 after purchasing an additional 2,854 shares in the last quarter. Calton & Associates Inc. boosted its position in Pfizer by 137.4% during the 1st quarter. Calton & Associates Inc. now owns 29,634 shares of the biopharmaceutical company's stock worth $751,000 after buying an additional 17,151 shares during the period. Finally, Kestra Private Wealth Services LLC boosted its position in Pfizer by 1.2% during the 1st quarter. Kestra Private Wealth Services LLC now owns 299,796 shares of the biopharmaceutical company's stock worth $7,597,000 after buying an additional 3,533 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. The Goldman Sachs Group boosted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets dropped their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Finally, HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Stock Down 0.8%

PFE traded down $0.21 during trading on Monday, reaching $24.27. The stock had a trading volume of 33,436,955 shares, compared to its average volume of 41,926,715. The stock's 50 day moving average is $24.07 and its two-hundred day moving average is $24.71. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $137.96 billion, a price-to-earnings ratio of 7.62, a P/E/G ratio of 0.89 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the company earned $0.82 EPS. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.09%. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.